| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Protalix BioTherapeutics Inc. (DE) | Pegunigalsidase alfa | Fabry disease | Phase 3 | Trial Completed | Intravenous | Genetic Disorder |
| Protalix BioTherapeutics Inc. (DE) | Pegunigalsidase alfa (PRX-102) - (BALANCE) | Fabry disease | Phase 3 | Data Released | Intravenous | Genetic Disorder |
| Protalix BioTherapeutics Inc. (DE) | PRX-115 | Severe Gout | Phase 2 | Trial Planned | Intravenous | Orthopedic |
| Protara Therapeutics Inc. | TARA-002 | Lymphatic Malformations (LMs) | Phase 3 | Trial Planned | Intravesical | N/A |
| Protara Therapeutics Inc. | TARA-002 | Lymphatic Malformations (LMs) | Phase 3 | Trial Planned | Intravesical | N/A |
| Protara Therapeutics Inc. | TARA-002 - (STARBORN-1) | Pediatric patients with lymphatic malformations (LMs) | Phase 2 | Data Released | Intravesical | N/A |
| Prothena Corporation plc | Coramitug (PRX004) - (CLEOPATTRA) | ATTR-cardiomyopathy | Phase 3 | Ongoing | intravenous | Cardiology |
| Prothena Corporation plc | Birtamimab - (AFFIRM-AL) | AL Amyloidosis | Phase 3 | Trial Discontinued | Intravenous | Hematology |